Background: Abnormal lipid profiles have been associated with gestational diabetes mellitus (GDM), but studies with longitudinal measures of lipids throughout pregnancy are sparse. The aim of the present study was to characterize longitudinal changes in lipid profiles throughout pregnancy and prospectively examine the associations of plasma lipid concentrations with risk of GDM. Methods: This study was a nested case-control study including 107 GDM cases and 214 matched non-GDM controls from participants in the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies -Singleton cohort. Blood samples were collected longitudinally at Gestational Weeks (GW) 10-14, 15-26 (fasting sample), 23-31, and 33-39. Plasma concentrations of triglycerides, total cholesterol, and high-density lipoprotein cholesterol (HDL-C) were measured by enzymatic assays. Low-density lipoprotein cholesterol (LDL-C) was calculated using Friedewald's formula. Results: Plasma triglycerides, total cholesterol, and LDL-C increased as pregnancy progressed. At GW 10-14, the adjusted odds ratios (aORs) of GDM comparing the highest versus lowest quartile were 3.15 (95% confidence interval [CI] 1.38-7.15; P trend = 0.002) for triglycerides and 0.44 (95% CI 0.18-1.09; P trend = 0.045) for HDL-C. At GW 15-26, the aORs were 6.57 (95% CI 2.25-19.17; P trend = 0.001) for triglycerides and 0.23 (95% CI 0.08-0.63; P trend = 0.005) for HDL-C. No significant associations were observed for total cholesterol and LDL-C concentrations with risk of GDM. Conclusions: Higher plasma triglyceride and lower HDL-C concentrations in early and mid-pregnancy were significantly associated with a greater risk of GDM. Total cholesterol and LDL-C concentrations during pregnancy were not significantly associated with GDM risk.
Introduction
Gestational diabetes mellitus (GDM), defined as glucose intolerance with onset or first recognition during pregnancy, is the most common metabolic condition during pregnancy. 1 In the US, GDM complicates approximately 9% of all pregnancies 2 and its prevalence is on the rise. 3, 4 Gestational diabetes mellitus is associated with short-and long-term adverse outcomes for both the mothers and their children. 1, 5 During pregnancy, a continuous supply of nutrients, regardless of intermittent maternal food consumption, is required for the growing fetus. As a result, pregnant women normally experience physiological changes in carbohydrate and lipid metabolism. 6, 7 Changes in maternal lipid metabolism may be related to adverse pregnancy and neonatal outcomes. 8, 9 However, previous studies on the associations of circulating lipid patterns during pregnancy with GDM risk have yielded mixed findings. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Most previous studies were designed as a cross-sectional comparison between women with GDM and those with normal pregnancies, with the majority using blood samples collected in the late second trimester or even the third trimester when GDM could have already been diagnosed. 10 Therefore, such studies lack insights into the temporal relationships between lipid disturbance and GDM incidence. Several prospective cohort studies have assessed circulating lipids at a certain time point in early pregnancy in relation to subsequent risk of GDM. [13] [14] [15] [16] [17] However, the associations of longitudinal trends of circulating lipids throughout pregnancy with risk of GDM remain poorly understood.
The primary objective of the present study was to prospectively examine the associations of maternal plasma lipids in the first and second trimesters with subsequent risk of GDM. In addition, we aimed to evaluate the longitudinal trend of plasma lipids across different trimesters in pregnancy.
Methods

Original cohort
The present study is a nested case-control study among participants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies -Singleton cohort, which is a multicenter prospective cohort study conducted by the NICHD between 2009 and 2013. 20 One of the secondary objectives of the NICHD Fetal Growth Studies -Singleton cohort was to collect blood samples throughout pregnancy for an etiologic study of GDM and related complications. The NICHD Fetal Growth Studies -Singleton cohort was approved by the institutional review boards of all participating institutions. All participants provided written informed consent.
In the NICHD Fetal Growth Studies -Singleton cohort, 2802 pregnant women representing four race/ ethnic groups, aged 18-40 years and who had a singleton pregnancy and a prepregnancy body mass index (BMI) ranging from 19 to 45 kg/m 2 were recruited from 12 clinical centers across the US. Women with HIV or major chronic conditions, such as prepregnancy hypertension, prepregnancy diabetes, cancer, or psychiatric, renal, or autoimmune diseases were excluded. Women were followed-up from enrollment until delivery using sonograms, anthropometric measurements, and questionnaires at each visit. Maternal venous blood samples were collected longitudinally during four selected study visits, which were scheduled at 8-13, 16-22, 24-29 and 34-37 weeks gestation during pregnancy; of these, the blood specimen collected at the second visit was a fasting sample. In order to obtain weekly biomarker data, participants were randomized to different follow-up schedules within each study visit time window. A few participants returned late for the originally scheduled visit; therefore, the actual gestational weeks (GW) at blood collection went slightly beyond the planned time windows, with ranges of 10-14, 15-26, 23-31, and 33-39 weeks, respectively. Plasma samples were processed immediately after collection and stored at −80 C until they were assayed.
Selection of cases and controls in the present nested case-control study
In the present study, all GDM cases (n = 107) identified from the NICHD Fetal Growth Studies -Singleton cohort were included. Gestational diabetes mellitus was diagnosed by the 3-h oral glucose tolerance test (OGTT) according to the criteria of the American College of Obstetrics and Gynecologists. 21 In all, 214 non-GDM controls were randomly selected and matched 2:1 to cases on age (AE2 years), race/ethnicity (nonHispanic White, non-Hispanic Black, Hispanic, Asian/ Pacific Islander), and gestational age at blood collection (AE2 weeks).
Exposure variables
Maternal plasma total cholesterol, high-density lipoprotein cholesterol (HDL-C), and triglycerides were measured using enzymatic assays and a Roche COBAS 6000 Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN, USA). Analytical interassay coefficients of variation for total cholesterol, HDL-C, and triglycerides were 2.2%, 3.2%, and 2.3%, respectively. Low-density lipoprotein cholesterol (LDL-C) was calculated using Friedewald's formula as follows: 22 LDL-C = total cholesterol -HDL-C -triglycerides=5
All plasma lipid concentrations were in mg/dL. All assays were performed at the University of Minnesota Advanced Research and Diagnostics Laboratory (Minneapolis, MN, USA), without knowledge of GDM status. For the first two visits prior to GDM diagnosis, plasma lipid concentrations were measured among all GDM cases and controls. For the two visits during or after GDM diagnosis, plasma lipid measurements were performed among all cases and in one of the matched controls.
Covariates
Information on maternal demographic, lifestyle, and medical characteristics was collected from questionnaires or retrieved from medical records. We included a priori selected covariates that are conventional risk factors for GDM, namely a family history of diabetes and prepregnancy BMI calculated from measured height and selfreported prepregnancy weight. To obtain conservative risk estimates, we also included two matching factors that were only matched within a certain range (i.e. maternal age and gestational age at blood collection). Race/ethnicity was matched exactly between GDM cases and controls and was not included in the multivariable model. In addition, we did not include maternal smoking status in the multivariable model because, according to the original cohort design, 20 non-obese women who smoked in the 6 months prior to pregnancy were not eligible for the cohort and, among obese participants, only five smoked in the 6 months prior to pregnancy.
Statistical analysis
Descriptive statistics are reported as the mean AE SD for continuous variables or as frequencies for categorical variables. Comparisons of participant characteristics between GDM cases and controls were performed by mixed-effect linear regression models for continuous variables and binomial or multinomial logistic regression with generalized estimating equations for binary or multilevel categorical variables, respectively, accounting for matched case-control pairs.
To assess the association of each plasma lipid variable with the risk of GDM, women were grouped according to quartiles based on the distribution of the lipid variable among the controls, with the lowest quartile as the reference group. To ensure that biomarker measurements preceded the diagnosis of GDM, we excluded one GDM case at GW 10-14 and five GDM cases at GW 15-26 from the final analysis because their blood samples were collected after the diagnosis of GDM. Odds ratios (ORs) of GDM and 95% confidence intervals (CIs) were calculated using multivariable conditional logistic regression models. We adjusted for age (continuous), gestational age at blood collection (continuous), family history of diabetes (yes/no), and prepregnancy BMI (<25.0, 25.0-25.9, 30.0-34.9, and 35.0-44.9 kg/m 2 ). Tests for linear trends in the ORs across quartiles of plasma lipids were conducted by assigning a median value for each quartile and fitting them as a continuous variable in the model.
Interaction tests were performed with multiplicative terms to evaluate whether the associations of maternal plasma lipids with GDM risk were modified by prepregnancy body weight status and family history of diabetes. To visualize the longitudinal changes in plasma lipid concentrations throughout pregnancy in GDM cases and controls, mean (AE SEM) concentrations of each biomarker were plotted against gestational age intervals of 2-3 weeks. Comparisons of the longitudinal changes between GDM cases and controls were performed using mixed-effect linear regression models accounting for matched case-control pairs.
All statistical analyses were performed using the SAS version 9.4 (SAS Institute, Cary, NC, USA). Two-tailed P < 0.05 was considered significant.
Results
Participant characteristics among GDM cases and matched controls in the present study have been described previously. 23 Briefly, compared with controls, women who developed GDM had greater prepregnancy BMI and were more likely to have a family history of diabetes. No statistically significant differences were observed in terms of education, type of health insurance, marital status, parity, smoking, and alcoholic beverage consumption (see Table S1 ).
Women who developed GDM had higher plasma concentrations of triglycerides, but lower concentrations of HDL-C (Fig. 1) . There was no significant difference in total cholesterol or LDL-cholesterol concentrations. Plasma concentrations of triglycerides and HDL-C at both 10-14 and 15-26 weeks gestation were significantly associated with subsequent risk of GDM (Table 1) . In the multivariable model, the adjusted ORs of GDM for plasma lipids across increasing quartiles were 1.00 (reference), 0.95, 1.92, and 3.15 (P trend = 0.002) for triglycerides and 1.00 (reference), 0.61, 0.46 and 0.44 (P trend = 0.045) for HDL-C at gestational weeks 10-14. At GW 15-26, the adjusted ORs were 1.00 (reference), 2.92, 5.32, and 6.57 (P trend = 0.001) for triglycerides and 1.00 (reference), 0.97, 0.73, and 0.23 (P trend = 0.005) for HDL-C. Additional adjustment for other lipid fractions modestly attenuated the observed associations. For example, at GW 10-14, the ORs of GDM comparing the highest versus lowest quartile were 2.70 (1.15-6.35) for triglycerides and 0.71 (0.28-1.81) for HDL-C after additional adjustment for other lipid fractions. At GW 15-26, the ORs were 6.75 (2.06-22.1) for triglycerides and 0.49 (0.15-1.59) for HDL-C. We observed no significant associations for plasma total cholesterol and LDL-C concentrations with risk of GDM. No significant effect modification by prepregnancy body weight status or family history of diabetes was observed (data not shown).
In analyses of longitudinal trends of plasma lipids throughout pregnancy, we observed a consistently lower concentration of HDL-C in GDM cases than controls, with significant differences at GW 13-15, 20-23, 24-27, and 32-35. For triglycerides, GDM cases showed a higher concentration on average than controls in the first and second trimesters, but there was no significant difference later (Fig. 2) . Longitudinal changes in total cholesterol and LDL-C concentrations were not significantly different between GDM cases and controls across pregnancy.
Discussion
Among women who were longitudinally followed-up from early pregnancy until delivery, we observed a positive association between plasma triglyceride concentrations and subsequent risk of GDM and an inverse association between plasma HDL-C concentrations and Multivariable conditional logistic regression models were used to estimate odds ratios (ORs) of gestational diabetes mellitus (GDM) and 95% confidence intervals (CIs). The range of biomarker concentrations given within each quartile is for non-GDM controls. *Adjusted for maternal age (years), gestational age at blood collection (weeks), parity, family history of diabetes (yes/no), and prepregnancy body mass index (<24.9, 25.0-25.9, 30.0-34.9, 35.0-44.9 kg/m 2 ). †
Timing of blood sample collection preceded the diagnosis of GDM. LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
risk of GDM. Comparing the longitudinal trends in plasma lipid concentrations throughout pregnancy in women who developed GDM with those who did not, we found that plasma HDL-C concentrations in GDM cases were consistently lower from early to late pregnancy and that plasma triglyceride concentrations were higher in the first and second trimesters among GDM cases than controls. To our knowledge, only two previous studies have profiled longitudinal changes of circulating lipid concentrations during pregnancy in women with and without GDM. 11, 12 However, both prior studies were based on a small sample size (one with nine and the other with 12 GDM cases), potentially compromising the statistical power required to identify significant associations between plasma lipids and GDM risk. The study by Montelongo et al. 11 including only nine GDM cases and 12 healthy controls, observed a significantly lower concentration of HDL-C in GDM cases than controls without finding a significant difference in triglyceride concentrations between cases and controls. Paradisi et al. 12 enrolled 50 high-risk pregnant women, of whom 12 developed GDM. A significantly greater risk of GDM was found in association with higher concentrations of triglycerides in the second trimester and LDL-C in the third trimester, whereas there were no significant associations between plasma lipid concentrations and risk of GDM during the first trimester. 12 The findings in the present study of prospective associations of plasma lipid concentrations in the first and second trimesters with risk of GDM are consistent with some, but not all, previous prospective studies. Similar to the results of the present study, Enquobahrie et al. 13 observed a positive association between triglyceride Figure 2 Mean (AE SEM) plasma concentrations of (a) total cholesterol, (b) high-density lipoprotein cholesterol (HDL-C), (c) low-density lipoprotein cholesterol (LDL-C), and (d) triglycerides according to gestational age intervals among women with gestational diabetes mellitus (GDM cases) and their matched controls. *P < 0.05, **P < 0.01, ***P < 0.001 compared with controls at the same gestational age (mixed-effect linear regression models).
concentrations at, on average, 13 weeks gestation and risk of developing GDM; however, they did not find a significant association for other lipids. Savvidou et al. 14 and Makgoba et al. 15 found that women who developed GDM had higher concentrations of triglycerides and lower concentrations of HDL-C in the first trimester. Zhou et al. 16 reported that lower HDL-C concentrations and higher triglyceride concentrations at 20 weeks gestation were associated with the development of GDM. In a previous study among obese pregnant women only, there was no significant associations between lipids in the first and early second trimesters and GDM. 17 In our subgroup analysis with obese women, we found a positive association between plasma triglyceride concentrations at GW 10-14 with subsequent risk of GDM (data not shown). Other studies (e.g. Sanchez-Vera et al. 18 and Nolan et al. 19 ) reported higher concentrations of triglycerides in women who developed GDM than in controls in univariate analysis, but the association was not significant in multivariable analysis. The differences in these study findings may be due, at least in part, to heterogeneity in study design and study methods, such as differences in gestational age at blood collection, fasting status, and diagnostic criteria for GDM, inconsistent or inadequate control for confounding, and variations in population characteristics. Consistent with the findings of the present study, a recent meta-analysis showed that women who developed GDM, compared with those without insulin resistance during pregnancy, had higher triglycerides across all three trimesters of pregnancy. 10 High-density lipoprotein cholesterol concentrations were significantly lower in women with GDM compared with women with normal pregnancy, but this difference was not observed in the first trimester. 10 More longitudinal studies with a large sample size are warranted to establish the role of lipids metabolism in the development of GDM across populations.
The observed associations of plasma lipids with GDM in the present study are biologically plausible, although precise mechanisms remain to be elucidated. During pregnancy, there are significant physiological changes in glucose and lipid metabolism. Changes in lipids and lipoproteins could be the result of increased maternal hormone concentrations and other maternal factors, such as prepregnancy BMI and gestational weight gain. [24] [25] [26] [27] Diareme et al. 28 reported that the rate of changes in individual plasma lipids varied during normal pregnancy, with triglycerides showing the largest increase and HDL-C the smallest. Similar to previous reports, 24 we observed an initial slow slope in the increase of triglyceride concentrations in the first trimester, followed by a large increase towards the second trimester and doubled concentrations in the third trimester, although not all triglyceride concentrations in the present study were measured in fasting samples. Human data illustrate that excessive triglyceride accumulation within skeletal muscles is linked with decreased insulin sensitivity, 29 which, in turn, may contribute to the development of GDM.
The present study has several strengths. It is nested in a prospective cohort with longitudinal assessments of maternal plasma lipid concentrations throughout pregnancy, which not only allows assessment of the temporal relation between lipid concentrations and the development of GDM, but also provides a unique opportunity to profile the longitudinal, gestational changes in lipids among GDM cases and matched controls. Compared with previous longitudinal studies on circulating lipids and GDM, 11, 12 the present study was relatively larger in sample size and better powered to detect the associations. The present study was conducted in a multiracial cohort, which may help establish generalizability of our findings. In addition, a fasting sample was taken in the present study during the study visit at 15-26 weeks gestation, which reduces the potential effect of food intake on plasma lipid concentrations.
We acknowledge that there are several limitations in the present study. First, we were unable to collect fasting samples for study visits other than at 15-26 weeks gestation given the feasibility issues and that it is particularly difficult for women to fast during pregnancy. As a result, the longitudinal trends of plasma lipid concentrations during pregnancy in the present study should be interpreted with caution. However, fasting status is unlikely to have an appreciable effect on the observed association. Several large population-based studies have determined that fasting times show little association with lipid subclass concentrations, 30, 31 and fasting has little effect on the overall association with clinical outcomes. 32, 33 Recently, a joint consensus statement from several European Societies even recommended routine use of non-fasting blood samples for the assessment of plasma lipid profiles, and emphasized that non-fasting and fasting blood lipids should be complementary. 34 Second, the prospective and longitudinal nature of the present study will reduce, but could not fully exclude, the possibility of reverse causation. It should also be noted that, by design, the present study excluded women with major chronic conditions, such as diabetes and cardiovascular diseases, from enrollment, which further lowers the possibility of reverse causation. Further investigation on the causal role of plasma lipids in GDM development is needed, especially given that a recent study 35 showed an inverse association of genetically elevated LDL-C, HDL-C, and triglycerides with type 2 diabetes risk. Third, although we have considered major confounders in the analysis, we could not rule out the possibility of potential residual confounding. For example, maternal adiposity is a shared risk factor for lipid disorders and GDM; although we adjusted for prepregnancy BMI, there may still be residual confounding from maternal adiposity.
In conclusion, in a longitudinal, multiracial/multiethnic study of pregnant women, we observed that higher plasma triglyceride and lower HDL-C concentrations in early and mid-pregnancy are significantly related to greater subsequent risk of GDM. Future research is warranted to investigate the interplays of dyslipidemia with biomarkers in other pathways in the etiology of GDM.
